Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos In Focus
Zacks Investment Research | Sep 10, 2019 10:49PM ET
It was a pretty ho-hum week for the biotech sector, with updates from only a few players. While Amgen (NASDAQ:AMGN) reported positive data on its lung cancer candidate, Alexion (NASDAQ:ALXN) signed a licensing deal with Eidos for amyloidosis drug. Meanwhile, there were a few updates from certain smaller biotechs as well.
Recap of the Week’s Most Important Stories:
Amgen Announces Promising Data on Lung Cancer Drug: Amgen Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More ).
Stay tuned for more pipeline updates.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.